Source: Therma Bright.
  • Therma Bright (THRM) has announced a C$6M private placement with institutional investors
  • The company will use the proceeds for general working capital purposes
  • It expects the placement to close on or about February 18, 2022
  • Therma Bright is a medical diagnostic and device technology company
  • Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share

Therma Bright (THRM) has announced a C$6M private placement with institutional investors.

The company will issue 20M units priced at $0.30 comprised of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one common share for $0.375 for five years following the issuance date.

The company will use the proceeds for general working capital purposes.

It expects the placement to close on or about February 18, 2022.

H.C. Wainwright & Co. is acting as the exclusive placement agent.

Therma Bright is a medical diagnostic and device technology company. It developed the AcuVid COVID-19 Rapid Antigen Saliva Test.

Therma Bright (THRM) is down by 16.67 per cent trading at $0.3125 per share as of 12:43 pm EST.

More From The Market Online

Cannabix delivers marijuana breath test to Eastern Canada workplace testing clinic

Cannabix Technologies (CSE:BLO) delivered its Marijuana Breath Test devices to a workplace drug and alcohol testing clinic in eastern Canada.

Loblaw taps Canadian company to scale AI operations

Grocery giant Loblaw (TSX:L) partners with Shakudo, a Canadian technology firm, to better align itself with the benefits of AI.

2 junior mining stocks for risk-averse investors

A deep dive into NovaRed Mining and The Metals Royalty Company, two junior mining stocks on de-risked paths to critical mineral wealth.